Larimar Therapeutics, Inc. has submitted the first module of its rolling Biologics License Application to the U.S. Food and Drug Administration for nomlabofusp, its investigational therapy for Friedreich’s ataxia. The submission follows FDA alignment from a Type B multidisciplinary pre-BLA meeting and comes alongside new long-term open-label data showing sustained increases in skin frataxin levels and directional clinical improvements across multiple Friedreich’s ataxia outcome measures. The update is clinically important because Friedreich’s ataxia remains a progressive, life-shortening neurological disease with no approved disease-modifying therapy that addresses the root cause of frataxin deficiency.
Why does Larimar’s rolling BLA submission matter for Friedreich’s ataxia patients?
Larimar’s rolling BLA submission matters because it moves nomlabofusp from a promising rare disease program into a more formal regulatory review pathway. The company has submitted the first module of its application for accelerated approval, with the remaining modules expected in the second half of 2026. For patients with Friedreich’s ataxia, that regulatory progress is significant because treatment options remain limited and do not yet include an approved therapy designed to restore or replace the deficient frataxin protein at the center of the disease.
Friedreich’s ataxia is caused by reduced frataxin, a mitochondrial protein needed for normal cellular energy production and iron-sulfur cluster biology. Deficiency leads to progressive neurological impairment, loss of coordination, fatigue, speech difficulty, cardiomyopathy and gradual loss of independence. Many patients experience worsening mobility over time, and the disease can affect both children and adults. A therapy that meaningfully raises frataxin levels could therefore represent a more direct disease-modifying approach.
Nomlabofusp is being developed as a recombinant fusion protein intended to deliver frataxin intracellularly. The clinical rationale is straightforward but ambitious: if the therapy can raise tissue frataxin levels and those increases are associated with clinical benefit, it may address a central disease mechanism rather than only managing symptoms. Larimar’s latest data and regulatory update suggest the company has built enough evidence for the FDA to review whether skin frataxin can support an accelerated approval submission as a novel surrogate endpoint.
The submission does not mean approval is guaranteed. The FDA has indicated that approval will be a matter of review, and the agency will assess the totality of evidence, including biomarker data, safety, clinical outcomes, manufacturing and confirmatory trial plans. Still, moving into a rolling BLA process gives the Friedreich’s ataxia community a clearer potential regulatory timeline than it had before.
How strong are the long-term frataxin data supporting nomlabofusp?
The long-term frataxin data are central to Larimar’s case because accelerated approval often depends on whether a surrogate endpoint is reasonably likely to predict clinical benefit. In the ongoing open-label study, daily nomlabofusp treatment increased and sustained skin frataxin levels over one year and 18 months. At the one-year time point, 100% of participants with available data, 9 of 9 patients, achieved and maintained skin frataxin levels above 50% of the mean level seen in healthy volunteers, a range Larimar describes as comparable to asymptomatic heterozygous carriers.
That threshold matters because Friedreich’s ataxia is fundamentally a frataxin-deficiency disorder. If treatment can raise tissue frataxin into a range associated with asymptomatic carriers, the biomarker argument becomes more compelling. The data also showed that skin frataxin levels reached apparent steady state with long-term dosing, which supports the biological plausibility of sustained exposure rather than a short-lived laboratory change.
Larimar also reported that the FDA reaffirmed its willingness to consider frataxin as a potential novel surrogate endpoint. The agency also noted that exposure-response analysis linking nomlabofusp exposure to clinical outcomes could support the BLA submission, while exploratory gene expression and lipid biomarker data may provide additional evidence beyond tissue frataxin concentrations.
The key question for reviewers will be whether skin frataxin is sufficiently connected to meaningful patient benefit. Skin is accessible for measurement, but Friedreich’s ataxia primarily affects the nervous system, heart and other tissues. Larimar’s argument is strengthened by the association between increased skin frataxin and directional improvements in clinical measures, but the FDA will still need to determine whether the biomarker package supports accelerated approval.
What do the clinical outcome measures suggest about potential patient benefit?
Larimar reported directional improvement across multiple Friedreich’s ataxia clinical outcome measures at one year of nomlabofusp treatment compared with worsening in a matched FACOMS natural history reference population. These measures included the modified Friedreich Ataxia Rating Scale, FARS-Activities of Daily Living, the 9-hole peg test and the Modified Fatigue Impact Scale. The company said 13 participants who completed one year of treatment showed a mean 1.0-point improvement in mFARS compared with a mean 1.6-point worsening in the FACOMS reference group, resulting in a 2.6-point difference.
At 18 months, Larimar reported a mean 2.3-point improvement in mFARS among seven participants compared with a calculated mean 2.3-point worsening in the FACOMS reference group, producing a calculated 4.6-point difference. These signals are clinically interesting because Friedreich’s ataxia is typically progressive. Stabilization alone can be meaningful in a disease where natural history shows decline, and directional improvement is especially notable if it is sustained.
Functional observations also matter. Among participants completing one year of dosing, one of six non-ambulatory patients at baseline became ambulatory, while none of the seven ambulatory participants progressed to non-ambulatory status. These are small numbers, but they are important because mobility is one of the most meaningful outcomes for patients and families.
The limitations should be clear. The study is open label, the sample size is small, and comparisons to a natural history reference population are not the same as a randomized placebo-controlled trial. The clinical findings are encouraging, but they will need to be interpreted carefully in the regulatory review and tested further in the global confirmatory Phase 3 study expected to dose its first patient in the third quarter of 2026.
Why is the safety profile important for nomlabofusp’s benefit-risk assessment?
Safety will be one of the most important issues in the FDA’s review because nomlabofusp is intended for long-term daily treatment in a rare neurological disease. Larimar reported that long-term dosing continues to be generally well tolerated, with more than 10,000 doses administered in the open-label study. The most common adverse events were local injection site reactions that were mild to moderate, decreased in frequency over time and did not lead to study withdrawals.
The most important safety concern is anaphylaxis. Larimar reported anaphylaxis in 10 of 43 patients, with 9 of the 10 having prior exposure to nomlabofusp in an earlier study. Among 11 participants with no prior exposure, one experienced anaphylaxis. All affected participants returned to their usual state of health after standard treatment, with no further sequelae reported.
This safety profile will require careful regulatory and clinical interpretation. Anaphylaxis is a serious event, particularly for a therapy intended for chronic use. The FDA and clinicians will need to evaluate risk mitigation, patient selection, monitoring procedures, premedication approaches if relevant, education and the feasibility of long-term administration in real-world settings.
The benefit-risk equation in Friedreich’s ataxia is also different from common conditions because of the severity and progressive nature of the disease. Patients and families may be willing to accept certain risks if a therapy has credible disease-modifying potential. However, approval and adoption will depend on whether the safety plan is practical and whether the clinical and biomarker evidence supports meaningful benefit.
How could accelerated approval shape the future Friedreich’s ataxia treatment landscape?
Accelerated approval could reshape the Friedreich’s ataxia treatment landscape by creating a regulatory path based on frataxin restoration rather than waiting for longer-term clinical outcomes alone. Rare neurological diseases often progress slowly enough that traditional trials can be difficult, lengthy and expensive. If the FDA accepts skin frataxin as a surrogate endpoint reasonably likely to predict clinical benefit, it could open a more practical path for therapies targeting the underlying biology of Friedreich’s ataxia.
That would be important not only for Larimar, but also for the broader rare disease field. A successful accelerated approval pathway would show how a mechanistically relevant biomarker, supportive clinical outcomes and a confirmatory trial plan can be combined for a disorder with severe unmet need. It could also encourage more investment in intracellular protein delivery and disease-rooted biomarker strategies.
For patients, the practical impact would depend on the final label, access, monitoring requirements and post-approval obligations. Larimar is targeting a potential mid-2027 launch if nomlabofusp is approved. That timeline remains conditional, but it gives the community a clearer sense of when a first disease-modifying option could potentially become available.
The confirmatory Phase 3 study remains essential. Accelerated approval requires post-approval verification of clinical benefit, and the FDA will be watching whether Larimar can execute the global study effectively. The long-term credibility of nomlabofusp will depend on whether biomarker changes translate into durable functional benefit across a broader Friedreich’s ataxia population.
What should clinicians and families watch next in the nomlabofusp program?
Clinicians and families should watch the completion of the rolling BLA submission, expected in the second half of 2026. The final modules, including manufacturing and additional regulatory materials, will be important because biologics review depends not only on clinical data but also on product quality, consistency and manufacturing readiness. For a recombinant fusion protein intended for chronic use, chemistry, manufacturing and controls will be closely examined.
The global confirmatory Phase 3 study is another major milestone. Larimar expects to dose the first patient in the third quarter of 2026. Study design, enrollment criteria, endpoint selection, geographic reach and treatment duration will determine how well the trial can verify clinical benefit. The trial will also help define how nomlabofusp performs in a broader population, including pediatric patients as the open-label protocol expands.
Families should also watch for more detail on safety management. The anaphylaxis signal will be central to real-world use if the therapy is approved. Clear guidance on monitoring, administration setting, emergency preparedness and patient counseling will be necessary to make treatment feasible and safe.
The most important regulatory question is whether the FDA concludes that the totality of nomlabofusp evidence supports accelerated approval. Larimar has now initiated the submission and reported encouraging long-term biomarker and clinical observations. The next stage will determine whether those data can translate into the first approved disease-modifying therapy designed to address the root cause of Friedreich’s ataxia.
Could Larimar be closer to changing the Friedreich’s ataxia treatment landscape? added by Soujanya Ravi on
View all posts by Soujanya Ravi →